- GlobeNewswire•12 days ago
COLUMBIA, Md., Feb. 10, 2017-- Osiris Therapeutics, Inc. is pleased to announce that its Board of Directors, at a Board Meeting on February 7 th, 2017, confirmed the appointment of Messrs. Uwe Sommer and ...
- GlobeNewswire•last monthOsiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal
COLUMBIA, Md., Jan. 19, 2017-- Osiris Therapeutics, Inc. announced today that the study“ A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two Different Human Placental Membrane Products ...
- GlobeNewswire•last monthOsiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md., Jan. 13, 2017-- Osiris Therapeutics, Inc., announced today that a new peer-reviewed manuscript“ Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with ...
L3Q.SG : Summary for Osiris Therapeutics Inc. Regist - Yahoo Finance
Osiris Therapeutics Inc. Regist (L3Q.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 6:05PM CET
|Bid||0.00 x 300000|
|Ask||0.00 x 300000|
|Day's Range||5.08 - 5.53|
|52 Week Range||3.57 - 6.57|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|